NO302170B1 - Enantiomerisk 1-fenyl-2-(2-pyridinyl)etylamin, farmasöytisk formulering og anvendelse derav - Google Patents

Enantiomerisk 1-fenyl-2-(2-pyridinyl)etylamin, farmasöytisk formulering og anvendelse derav

Info

Publication number
NO302170B1
NO302170B1 NO943645A NO943645A NO302170B1 NO 302170 B1 NO302170 B1 NO 302170B1 NO 943645 A NO943645 A NO 943645A NO 943645 A NO943645 A NO 943645A NO 302170 B1 NO302170 B1 NO 302170B1
Authority
NO
Norway
Prior art keywords
phenyl
enantiomeric
ethylamine
pyridinyl
pharmaceutical formulation
Prior art date
Application number
NO943645A
Other languages
English (en)
Norwegian (no)
Other versions
NO943645D0 (no
NO943645L (no
Inventor
Ronald Conrad Griffith
Robert John Murray
Michael Balestra
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO943645D0 publication Critical patent/NO943645D0/no
Publication of NO943645L publication Critical patent/NO943645L/no
Publication of NO302170B1 publication Critical patent/NO302170B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO943645A 1992-04-03 1994-09-30 Enantiomerisk 1-fenyl-2-(2-pyridinyl)etylamin, farmasöytisk formulering og anvendelse derav NO302170B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties
PCT/GB1993/000689 WO1993020052A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders

Publications (3)

Publication Number Publication Date
NO943645D0 NO943645D0 (no) 1994-09-30
NO943645L NO943645L (no) 1994-11-16
NO302170B1 true NO302170B1 (no) 1998-02-02

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943645A NO302170B1 (no) 1992-04-03 1994-09-30 Enantiomerisk 1-fenyl-2-(2-pyridinyl)etylamin, farmasöytisk formulering og anvendelse derav

Country Status (29)

Country Link
EP (1) EP0633879B1 (cs)
JP (2) JP3120810B2 (cs)
KR (1) KR100259567B1 (cs)
CN (1) CN1044367C (cs)
AT (1) ATE163925T1 (cs)
AU (2) AU3897693A (cs)
CA (1) CA2133427C (cs)
CZ (1) CZ288519B6 (cs)
DE (1) DE69317411T2 (cs)
DK (1) DK0633879T3 (cs)
DZ (1) DZ1677A1 (cs)
ES (1) ES2115055T3 (cs)
FI (1) FI105025B (cs)
HK (1) HK1009331A1 (cs)
HU (1) HU211529A9 (cs)
IL (1) IL105276A (cs)
MA (1) MA22866A1 (cs)
MX (1) MX9301935A (cs)
MY (1) MY110149A (cs)
NO (1) NO302170B1 (cs)
NZ (1) NZ251384A (cs)
PL (1) PL180014B1 (cs)
RU (1) RU2128650C1 (cs)
SG (1) SG47948A1 (cs)
SK (1) SK281258B6 (cs)
TW (1) TW282455B (cs)
UA (1) UA29437C2 (cs)
WO (1) WO1993020052A1 (cs)
ZA (1) ZA932415B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
SG52662A1 (en) * 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
NZ593282A (en) * 2008-12-24 2013-06-28 Astrazeneca Ab Ethanamine compounds and their use for treating depression
JP2015501652A (ja) 2011-12-14 2015-01-19 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇａｂｒ−ａ２診断
JP6479834B2 (ja) * 2013-11-05 2019-03-06 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｎｍｄａアンタゴニストプロドラッグ
MX2022016183A (es) * 2020-06-23 2023-02-13 Biohaven Therapeutics Ltd Formulaciones topicas de (1s)-1-fenil-2-piridin-2-iletanamina.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG52662A1 (en) * 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties

Also Published As

Publication number Publication date
JP3120810B2 (ja) 2000-12-25
AU705419B2 (en) 1999-05-20
UA29437C2 (uk) 2000-11-15
AU3897693A (en) 1993-11-08
NO943645D0 (no) 1994-09-30
ES2115055T3 (es) 1998-06-16
IL105276A (en) 1997-06-10
IL105276A0 (en) 1993-08-18
NZ251384A (en) 1996-10-28
CN1044367C (zh) 1999-07-28
JPH07505385A (ja) 1995-06-15
ZA932415B (en) 1993-10-22
EP0633879A1 (en) 1995-01-18
KR100259567B1 (ko) 2000-07-01
DE69317411T2 (de) 1998-07-30
WO1993020052A1 (en) 1993-10-14
HU211529A9 (en) 1995-11-28
SG47948A1 (en) 1998-04-17
EP0633879B1 (en) 1998-03-11
FI944546A (fi) 1994-09-30
CN1081669A (zh) 1994-02-09
MX9301935A (es) 1994-08-31
SK117794A3 (en) 1995-05-10
RU2128650C1 (ru) 1999-04-10
RU94042465A (ru) 1996-07-20
CZ240994A3 (en) 1995-12-13
CZ288519B6 (cs) 2001-07-11
DZ1677A1 (fr) 2002-02-17
ATE163925T1 (de) 1998-03-15
AU7545696A (en) 1997-02-13
FI944546A0 (fi) 1994-09-30
HK1009331A1 (en) 1999-05-28
CA2133427C (en) 2003-06-10
TW282455B (cs) 1996-08-01
DE69317411D1 (de) 1998-04-16
CA2133427A1 (en) 1993-10-14
DK0633879T3 (da) 1998-09-28
FI105025B (fi) 2000-05-31
MA22866A1 (fr) 1993-12-31
MY110149A (en) 1998-02-28
PL180014B1 (pl) 2000-11-30
NO943645L (no) 1994-11-16
SK281258B6 (sk) 2001-01-18
JP2000319259A (ja) 2000-11-21

Similar Documents

Publication Publication Date Title
IS3720A7 (is) Afleiður dialkoxy-pyridinyl-benzimidazole, aðferðvið lögun þeirra og lyfjafræðileg notkun
DK0959888T3 (da) Anvendelse af det chelerende middel clioquinol til fremstillingen af et farmaceutisk præparat til behandlingen af Alzheimer's sygdom
NO307092B1 (no) Sordaridin-derivater, anvendelse derav og farmasoeytisk blanding
NO302170B1 (no) Enantiomerisk 1-fenyl-2-(2-pyridinyl)etylamin, farmasöytisk formulering og anvendelse derav
DK0520200T3 (da) Imadazol-forbindelser, deres fremstilling og anvendelse
DK0573492T3 (da) Præparater indeholdende fluticasonpropionat og oxiconazol eller salte deraf til topisk administration
NO305286B1 (no) Kinoksalinforbindelser, farmas°ytiske preparater som omfatter dem, og anvendelse derav for fremstilling av medikamenter
DK0909763T3 (da) Colchicin-derivater og terapeutisk anvendelse deraf
ITMI911470A0 (it) N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico
NO303637B1 (no) 7-disubstituert-metyl-4-okso-3H,5H-pyrrolo-£3,2-d|pyrimidin, farmas°ytisk preparat, og anvendelse derav
NO304985B1 (no) Bicyklopolyazamakrocyklofosfonsyrer, deres komplekser og farmas°ytisk formulering
AU647608B2 (en) Isoxazolylimidazole derivatives, process for their production and their use in pharmaceutical agents
DK0637956T3 (da) Anvendelse af remacemid til behandling af Parkinsonˆs sygdom
NO983492D0 (no) 2,3-disubstituerte cyklopentanderivater, fremgangsmÕte for fremstilling derav, og medisinsk anvendelse derav
IT1276321B1 (it) Derivati del carbossimetilidenecicloptimmidazolo procedimento di fabbricazione dei derivati e agenti terapeutici che contengono
TH13285EX (th) สารประกอบที่ใช้บำบัดโรคที่เกี่ยวกับการเสื่อมของประสาท
GR920100469A (el) Ανταγωνιστές 5-ΗΤ4 βενζοδιοξανο οξαδιαζόλης.
ITGE940025A0 (it) Preparazione farmaceutica ad uso topico per la cura della psoriasi e di altre dermatosi.
IT1263076B (it) Uso orale e topico della n-acetil-5-metossitriptamina (melatonina) nella terapia della psoriasi volgare.

Legal Events

Date Code Title Description
MK1K Patent expired